Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy

Background: Survival outcomes after primary radiotherapy for localized prostate cancer (PCa) are excellent, regardless of the specific treatment modality. For this reason, health-related quality of life (HRQOL) has come to play an ever more important role in treatment selection. Stereotactic body ra...

Full description

Bibliographic Details
Main Authors: Piotr Milecki, Anna Adamska, Anna Rucinska, Grzegorz Pałucki, Agnieszka Szumiło, Agnieszka Skrobała, Agata Jodda, Michał Michalak
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Journal of Personalized Medicine
Subjects:
Online Access:https://www.mdpi.com/2075-4426/13/2/233
_version_ 1797619942021922816
author Piotr Milecki
Anna Adamska
Anna Rucinska
Grzegorz Pałucki
Agnieszka Szumiło
Agnieszka Skrobała
Agata Jodda
Michał Michalak
author_facet Piotr Milecki
Anna Adamska
Anna Rucinska
Grzegorz Pałucki
Agnieszka Szumiło
Agnieszka Skrobała
Agata Jodda
Michał Michalak
author_sort Piotr Milecki
collection DOAJ
description Background: Survival outcomes after primary radiotherapy for localized prostate cancer (PCa) are excellent, regardless of the specific treatment modality. For this reason, health-related quality of life (HRQOL) has come to play an ever more important role in treatment selection. Stereotactic body radiation therapy (SBRT) is increasingly used to treat patients with PCa. However, the impact of prostate volume on HRQOL is not clear. In this study, we aimed to determine whether a large prostate volume negatively influences HRQOL outcomes in patients undergoing ultrahypofractionated SBRT. Material and Methods: We conducted a prospective study of 530 men with low- and intermediate-risk localized PCa. All patients were treated from 2013 to 2017 with SBRT (Cyberknife system). HRQOL data were collected at baseline (pre-treatment), immediately after treatment, and at 12 and 24 months. QOL variables were assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 and PR-25 module. Differences in the QLQ-C30 scales were considered clinically relevant when the change was >10 points. For the analysis, patients were classified into two groups according to prostate volume (≤60 vs. >60 cm<sup>3</sup>). Results: The prostate volume was ≤60 cm<sup>3</sup> in 415 patients (78.3%) and >60 cm<sup>3</sup> in 115 (21.7%). No between-group differences were observed at baseline for any of the following variables: clinical stage; hormonal therapy; marital status; educational level; or employment status. No clinically-significant deterioration (functional and symptom scales) was observed in either group between the baseline and 24-month assessment. There were no clinically-relevant differences between the groups on any of the HRQOL variables, regardless of the prostate volume. Conclusions: This study shows that a large prostate volume (>60 cm<sup>3</sup>) does not appear to negatively impact HRQOL outcomes at two years in patients with localized prostate cancer treated with ultrahypofractionated SBRT administered with the CyberKnife system.
first_indexed 2024-03-11T08:34:12Z
format Article
id doaj.art-075798c659ae4bf196ec5b55b2a02ef5
institution Directory Open Access Journal
issn 2075-4426
language English
last_indexed 2024-03-11T08:34:12Z
publishDate 2023-01-01
publisher MDPI AG
record_format Article
series Journal of Personalized Medicine
spelling doaj.art-075798c659ae4bf196ec5b55b2a02ef52023-11-16T21:32:34ZengMDPI AGJournal of Personalized Medicine2075-44262023-01-0113223310.3390/jpm13020233Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body RadiotherapyPiotr Milecki0Anna Adamska1Anna Rucinska2Grzegorz Pałucki3Agnieszka Szumiło4Agnieszka Skrobała5Agata Jodda6Michał Michalak71st Radiotherapy Department, Greater Poland Cancer Centre, 61-866 Poznań, Poland1st Radiotherapy Department, Greater Poland Cancer Centre, 61-866 Poznań, Poland1st Radiotherapy Department, Greater Poland Cancer Centre, 61-866 Poznań, Poland1st Radiotherapy Department, Greater Poland Cancer Centre, 61-866 Poznań, Poland1st Radiotherapy Department, Greater Poland Cancer Centre, 61-866 Poznań, PolandChair of Electroradiology, Faculty of Medicine, Poznan University of Medical Sciences, 60-780 Poznań, PolandDepartment of Medical Physics, Greater Poland Cancer Centre, 61-866 Poznań, PolandDepartment of Statistics, Faculty of Medicine, Poznan University of Medical Sciences, 60-780 Poznań, PolandBackground: Survival outcomes after primary radiotherapy for localized prostate cancer (PCa) are excellent, regardless of the specific treatment modality. For this reason, health-related quality of life (HRQOL) has come to play an ever more important role in treatment selection. Stereotactic body radiation therapy (SBRT) is increasingly used to treat patients with PCa. However, the impact of prostate volume on HRQOL is not clear. In this study, we aimed to determine whether a large prostate volume negatively influences HRQOL outcomes in patients undergoing ultrahypofractionated SBRT. Material and Methods: We conducted a prospective study of 530 men with low- and intermediate-risk localized PCa. All patients were treated from 2013 to 2017 with SBRT (Cyberknife system). HRQOL data were collected at baseline (pre-treatment), immediately after treatment, and at 12 and 24 months. QOL variables were assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 and PR-25 module. Differences in the QLQ-C30 scales were considered clinically relevant when the change was >10 points. For the analysis, patients were classified into two groups according to prostate volume (≤60 vs. >60 cm<sup>3</sup>). Results: The prostate volume was ≤60 cm<sup>3</sup> in 415 patients (78.3%) and >60 cm<sup>3</sup> in 115 (21.7%). No between-group differences were observed at baseline for any of the following variables: clinical stage; hormonal therapy; marital status; educational level; or employment status. No clinically-significant deterioration (functional and symptom scales) was observed in either group between the baseline and 24-month assessment. There were no clinically-relevant differences between the groups on any of the HRQOL variables, regardless of the prostate volume. Conclusions: This study shows that a large prostate volume (>60 cm<sup>3</sup>) does not appear to negatively impact HRQOL outcomes at two years in patients with localized prostate cancer treated with ultrahypofractionated SBRT administered with the CyberKnife system.https://www.mdpi.com/2075-4426/13/2/233prostate cancerprostate volumequality of lifestereotactic radiotherapycyberknife
spellingShingle Piotr Milecki
Anna Adamska
Anna Rucinska
Grzegorz Pałucki
Agnieszka Szumiło
Agnieszka Skrobała
Agata Jodda
Michał Michalak
Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
Journal of Personalized Medicine
prostate cancer
prostate volume
quality of life
stereotactic radiotherapy
cyberknife
title Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
title_full Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
title_fullStr Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
title_full_unstemmed Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
title_short Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
title_sort large prostate volume does not negatively impact health related quality of life in patients with prostate cancer treated with ultrahypofractionated stereotactic body radiotherapy
topic prostate cancer
prostate volume
quality of life
stereotactic radiotherapy
cyberknife
url https://www.mdpi.com/2075-4426/13/2/233
work_keys_str_mv AT piotrmilecki largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT annaadamska largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT annarucinska largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT grzegorzpałucki largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT agnieszkaszumiło largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT agnieszkaskrobała largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT agatajodda largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy
AT michałmichalak largeprostatevolumedoesnotnegativelyimpacthealthrelatedqualityoflifeinpatientswithprostatecancertreatedwithultrahypofractionatedstereotacticbodyradiotherapy